|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期2017-08-29 |
|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期2014-08-06 |
|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期2011-01-01 |
Open-label, Multicenter, multinAtionaL, inteRventional Clinical Trial to Assess Efficacy and Safety of the exteMporaneous combInation of Nebivolol and Ramipril in hypertenSIve pAtients - ARTEMISIA Study
Open-label, inteRventional clinical Trial to assess EffIcacy and safety of the exteMporaneous combInation of Nebivolol and Ramipril in hypertenSIve pAtients.
Open-label, multicenter, multinational, interventional Clinical Trial to assess Efficacy and Safety of the extemporaneous combination of Nebivolol and Ramipril in hypertensive patients - ARTEMISIA study - ARTEMISIA study
Open-laBel, Multicenter, multinatiOnal, inTerventional Clinical Trial to Assess effIcacy and Safety of the Extemporaneous Combination of nEbivoLol and amLodipine in Grade 1-2 Hypertensive patIents Versus Each Monotherapy
Study to assess the anti-hypertensive efficacy and safety of the extemporaneous combination of Nebivolol 5 mg in combination with Amlodipine 5 mg or AML 10 mg in lowering the sitting diastolic BP after 8 weeks of treatment inpatients with uncontrolled BP previously treated with Nebivolol (NEB) or Amlodipine (5 mg) monotherapies for at least 4 weeks.
100 项与 Menarini International Operations Luxembourg SA 相关的临床结果
0 项与 Menarini International Operations Luxembourg SA 相关的专利(医药)
100 项与 Menarini International Operations Luxembourg SA 相关的药物交易
100 项与 Menarini International Operations Luxembourg SA 相关的转化医学